Clinical Trials on Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy in Japan
Total 9 results
-
Astellas Pharma IncCompletedChronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedChronic Renal Failure Patients With Hyperphosphataemia Receiving HemodialysisJapan
-
Astellas Pharma IncCompletedPatients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy | Pharmacodynamics of ASP7991 | Pharmacokinetics of ASP7991Japan
-
Astellas Pharma IncCompletedAnemia in Chronic Kidney Disease Patients Not on DialysisJapan
-
Astellas Pharma IncFibroGenCompletedPeritoneal Dialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Astellas Pharma IncFibroGenCompletedHemodialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Astellas Pharma IncFibroGenCompletedESA-naive Hemodialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Astellas Pharma IncFibroGenCompletedHemodialysis Patients With Renal AnemiaJapan
-
Novartis PharmaceuticalsCompletedHemodialysis | Renal Replacement Therapy | End Stage Renal Disease (ESRD) | Renal Transplantation | Chronic Kidney Disease (CKD)Germany, United States, Belgium, Italy, Spain, Croatia, Taiwan, Australia, Austria, Greece, Korea, Republic of, Lebanon, Czechia, Israel, Netherlands, Slovenia, Switzerland, Thailand, Norway, Turkey, Sweden, Argentina, Brazil, Japan, Se... and more